Trivalent influenza vaccine and febrile adverse events in Australia, 2010: clinical features and potential mechanisms.

[1]  J. Stockman.  Burden of Seasonal Influenza Hospitalization in Children, United States, 2003 to 2008 , 2012 .

[2]  T. Weeramanthri,et al.  Epidemiological study of severe febrile reactions in young children in Western Australia caused by a 2010 trivalent inactivated influenza vaccine , 2011, BMJ Open.

[3]  W. Schaffner,et al.  Burden of seasonal influenza hospitalization in children, United States, 2003 to 2008. , 2010, The Journal of pediatrics.

[4]  M. Holtzman,et al.  Detection of respiratory viruses and the associated chemokine responses in serious acute respiratory illness , 2010, Thorax.

[5]  H. Kelly,et al.  Lessons from the first year of the WAIVE study investigating the protective effect of influenza vaccine against laboratory‐confirmed influenza in hospitalised children aged 6–59 months , 2010, Influenza and other respiratory viruses.

[6]  P. Österlund,et al.  Pandemic H1N1 2009 Influenza A Virus Induces Weak Cytokine Responses in Human Macrophages and Dendritic Cells and Is Highly Sensitive to the Antiviral Actions of Interferons , 2009, Journal of Virology.

[7]  K. Edwards,et al.  Serious adverse events rarely reported after trivalent inactivated influenza vaccine (TIV) in children 6-23 months of age. , 2009, Vaccine.

[8]  J. Stockman.  Safety of Trivalent Inactivated Influenza Vaccine in Children 6 to 23 Months Old , 2008 .

[9]  Robert L Davis,et al.  Safety of trivalent inactivated influenza vaccine in children 6 to 23 months old. , 2006, JAMA.

[10]  M. Braun,et al.  Adverse Events After Inactivated Influenza Vaccination Among Children Less Than 2 Years of Age: Analysis of Reports From the Vaccine Adverse Event Reporting System, 1990–2003 , 2005, Pediatrics.

[11]  M. Buttmann,et al.  Interferon-β induces transient systemic IP-10/CXCL10 chemokine release in patients with multiple sclerosis , 2004, Journal of Neuroimmunology.

[12]  Robert L Davis,et al.  Safety of the trivalent inactivated influenza vaccine among children: a population-based study. , 2004, Archives of pediatrics & adolescent medicine.

[13]  M. Gold,et al.  Generalized convulsive seizure as an adverse event following immunization: case definition and guidelines for data collection, analysis, and presentation. , 2004, Vaccine.

[14]  M. Buttmann,et al.  Interferon-beta induces transient systemic IP-10/CXCL10 chemokine release in patients with multiple sclerosis. , 2004, Journal of neuroimmunology.

[15]  M. Matsuo,et al.  Possible contribution of interferon-α to febrile seizures in influenza , 2002 .

[16]  M. Matsuo,et al.  Possible contribution of interferon-alpha to febrile seizures in influenza. , 2002, Pediatric Neurology.

[17]  D. Gemsa,et al.  Differential mononuclear leukocyte attracting chemokine production after stimulation with active and inactivated influenza A virus. , 1998, Cellular immunology.

[18]  F. Hayden,et al.  Local and systemic cytokine responses during experimental human influenza A virus infection. Relation to symptom formation and host defense. , 1998, The Journal of clinical investigation.

[19]  M. Woynarowski,et al.  Seizures in children during interferon alpha therapy. , 1997, Journal of hepatology.

[20]  J. Hoofnagle,et al.  Seizures during alpha interferon therapy. , 1996, Journal of hepatology.

[21]  H. Janssen,et al.  Seizures associated with low-dose α-interferon , 1990, The Lancet.

[22]  H. Janssen,et al.  Seizures associated with low-dose alpha-interferon. , 1990, Lancet.